81.23 USD
+2.81 (+3.58%)
At close: Feb 6, 2026
81.5 USD
+0.27 (+0.33%)
After Hours: 2/6/2026, 8:00:01 PM
Overall HALO gets a fundamental rating of 7 out of 10. We evaluated HALO against 525 industry peers in the Biotechnology industry. HALO has an excellent profitability rating, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: HALO is growing strongly while it also seems undervalued. With these ratings, HALO could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
- HALO had positive earnings in the past year.
- HALO had a positive operating cash flow in the past year.
- In the past 5 years HALO has always been profitable.
- HALO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of HALO (26.81%) is better than 97.71% of its industry peers.
- With an excellent Return On Equity value of 118.17%, HALO belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 42.77%, HALO belongs to the best of the industry, outperforming 99.24% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 18.12%.
- The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
- HALO has a Profit Margin of 47.91%. This is amongst the best in the industry. HALO outperforms 98.28% of its industry peers.
- HALO's Profit Margin has declined in the last couple of years.
- HALO's Operating Margin of 59.33% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
- In the last couple of years the Operating Margin of HALO has declined.
- The Gross Margin of HALO (84.55%) is better than 87.21% of its industry peers.
- HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
- HALO has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, HALO has less shares outstanding
- Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
- HALO has an Altman-Z score of 5.46. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
- HALO's Altman-Z score of 5.46 is fine compared to the rest of the industry. HALO outperforms 75.19% of its industry peers.
- The Debt to FCF ratio of HALO is 2.51, which is a good value as it means it would take HALO, 2.51 years of fcf income to pay off all of its debts.
- HALO's Debt to FCF ratio of 2.51 is amongst the best of the industry. HALO outperforms 93.13% of its industry peers.
- HALO has a Debt/Equity ratio of 1.59. This is a high value indicating a heavy dependency on external financing.
- HALO's Debt to Equity ratio of 1.59 is on the low side compared to the rest of the industry. HALO is outperformed by 76.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.46 |
ROIC/WACC5.32
WACC8.04%
2.3 Liquidity
- HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- HALO has a worse Current ratio (1.59) than 79.58% of its industry peers.
- A Quick Ratio of 1.37 indicates that HALO should not have too much problems paying its short term obligations.
- HALO's Quick ratio of 1.37 is on the low side compared to the rest of the industry. HALO is outperformed by 80.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 48.55% over the past year.
- Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
- Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
- HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
- Based on estimates for the next years, HALO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.78% on average per year.
- HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.23% yearly.
EPS Next Y50.81%
EPS Next 2Y40.55%
EPS Next 3Y32.4%
EPS Next 5Y17.78%
Revenue Next Year33.53%
Revenue Next 2Y29.85%
Revenue Next 3Y23.95%
Revenue Next 5Y13.23%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.43, the valuation of HALO can be described as correct.
- 96.56% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
- HALO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.92.
- A Price/Forward Earnings ratio of 9.72 indicates a reasonable valuation of HALO.
- Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.47% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (27.78), we can say HALO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.43 | ||
| Fwd PE | 9.72 |
4.2 Price Multiples
- HALO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HALO is cheaper than 96.56% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.95% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.86 | ||
| EV/EBITDA | 11.9 |
4.3 Compensation for Growth
- HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of HALO may justify a higher PE ratio.
- A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.40% in the coming years.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y40.55%
EPS Next 3Y32.4%
5. Dividend
5.1 Amount
- No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
81.23
+2.81 (+3.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners105.85%
Inst Owner Change-2.25%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap9.55B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target79.56 (-2.06%)
Short Float %11.69%
Short Ratio6.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)1.48%
PT rev (3m)1.93%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)1.13%
EPS NY rev (1m)-0.32%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)1.35%
Revenue NY rev (1m)-0.22%
Revenue NY rev (3m)1.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.43 | ||
| Fwd PE | 9.72 | ||
| P/S | 7.69 | ||
| P/FCF | 15.86 | ||
| P/OCF | 15.63 | ||
| P/B | 18.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.9 |
EPS(TTM)5.63
EY6.93%
EPS(NY)8.36
Fwd EY10.29%
FCF(TTM)5.12
FCFY6.31%
OCF(TTM)5.2
OCFY6.4%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.28
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.46 |
F-Score8
WACC8.04%
ROIC/WACC5.32
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y50.81%
EPS Next 2Y40.55%
EPS Next 3Y32.4%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.53%
Revenue Next 2Y29.85%
Revenue Next 3Y23.95%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
Can you provide the valuation status for HALOZYME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.
Can you provide the expected EPS growth for HALO stock?
The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 50.81% in the next year.